1. Scrip
  2. >>Business
  3. >>Strategy

Restructuring On The Table For FibroGen After Roxadustat Rejection

 
• By Alaric DeArment

As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.

Malekidneys-cancer
The FDA issued a complete response letter for FibroGen and AstraZeneca's roxadustat in anemia of chronic kidney disease • Source: Shutterstock

With the US Food and Drug Administration rejecting FibroGen, Inc./AstraZeneca PLC’s roxadustat for anemia in chronic kidney disease (CKD), as expected, FibroGen may be forced to restructure, shifting its attention to Phase III pipeline asset pamrevlumab if the partners choose not to conduct a new clinical trial that could support US approval. Meanwhile, the drug’s setback could create an opening for competitors, particularly GlaxoSmithKline plc’s daprodustat and Akebia Therapeutics, Inc.’s vadadustat.

San Francisco-based FibroGen said 11 August that the FDA issued a complete response letter (CRL), requesting the company and AstraZeneca...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

More from Business

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.